- Home
- WING vs BPMC Comparison
WING vs BPMC Comparison
Compare WING & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WING
- BPMC
- Stock Information
- Founded
- WING 1994
- BPMC 2008
- Country
- WING United States
- BPMC United States
- Employees
- WING N/A
- BPMC N/A
- Industry
- WING Restaurants
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- WING Consumer Discretionary
- BPMC Health Care
- Exchange
- WING Nasdaq
- BPMC Nasdaq
- Market Cap
- WING 6.1B
- BPMC 5.8B
- IPO Year
- WING 2015
- BPMC 2015
- Fundamental
- Price
- WING $267.34
- BPMC $97.17
- Analyst Decision
- WING Buy
- BPMC Buy
- Analyst Count
- WING 18
- BPMC 21
- Target Price
- WING $322.83
- BPMC $124.05
- AVG Volume (30 Days)
- WING 878.2K
- BPMC 988.9K
- Earning Date
- WING 04-30-2025
- BPMC 05-01-2025
- Dividend Yield
- WING 0.40%
- BPMC N/A
- EPS Growth
- WING 110.47
- BPMC N/A
- EPS
- WING 5.91
- BPMC N/A
- Revenue
- WING $651,112,000.00
- BPMC $562,121,000.00
- Revenue This Year
- WING $19.47
- BPMC $44.85
- Revenue Next Year
- WING $17.36
- BPMC $32.06
- P/E Ratio
- WING $45.24
- BPMC N/A
- Revenue Growth
- WING 30.98
- BPMC 99.19
- 52 Week Low
- WING $204.00
- BPMC $73.04
- 52 Week High
- WING $433.86
- BPMC $121.90
- Technical
- Relative Strength Index (RSI)
- WING 62.60
- BPMC 59.54
- Support Level
- WING $264.00
- BPMC $87.03
- Resistance Level
- WING $278.44
- BPMC $104.86
- Average True Range (ATR)
- WING 10.98
- BPMC 3.86
- MACD
- WING 4.48
- BPMC 1.24
- Stochastic Oscillator
- WING 84.65
- BPMC 64.38
About WING Wingstop Inc.
Founded in 1994 in Garland, Texas, Wingstop is a restaurant operator specializing in indulgent bone-in and boneless chicken wings, chicken tenders, fries, and, recently, chicken sandwiches. The firm's footprint has grown quickly since its inception, reaching north of 2,560 global stores at the end of 2024. With a 98% franchised model, Wingstop generates the lion share of its revenue from franchise royalties and advertising fees, with the remainder derived from a small footprint of company-owned stores.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.